Accelerating geneLEAD for Airport and Infectious Disease Screening
First written in FY2021. 1 of 2 entries say "Advanced", first in FY2023. Latest entry: FY2023.
4 other companies' latest entry also says "Advanced".
- FY2023AdvancedAnnual report
「This project will accelerate our fully automated PCR testing system, geneLEAD, which has sold approximately 2,000 units in clinical settings across 50 countries worldwide, to meet new market needs.」
geneLEAD’s sales track record was updated from more than 1,000 units to approximately 2,000 units, while the development policy of accelerating the system for airport entry and exit controls and infectious disease screening remained in place. - FY2021First statedAnnual report
「This project will accelerate PSS’s fully automated PCR testing system, geneLEAD, which has sold more than 1,000 units in clinical settings across 50 countries worldwide, to meet new market needs. Intended applications of the technology include ① airport entry and exit controls and ② infectious disease screening, including COVID-19, where rapid and accurate PCR testing for negative and positive results is required.」
A new theme was presented to accelerate geneLEAD, which has an established sales track record, for use in airport entry and exit controls and infectious disease screening.